Ipsen Sa S/Adr (IPSEY) Q1 2026 Earnings Call

Investor webinar replay

Replay transcript excerpt

Hello and welcome to Ibsen's conference call and webcast on Q1 2026 results. I'll now hand you over to David Lowe, Ibsen's CEO. Thank you, operator, and hello everyone. I'm pleased to welcome you this afternoon to our Q1 sales presentation, which can also be found on Ibsen.com. Please turn to slide two. Please take note of our forward-looking statements, which outline the routine risks and uncertainties contained within this presentation. Also, All of my comments on growth will be based on constant exchange rates. Please turn to slide three. I'm going to take you through our first quarter sales performance and provide you with a business update, after which our CFO, Aymeric Le Chatelier, will join me for the Q&A session. Let's begin by taking a look at today's highlights. Please turn to slide four. We delivered a strong top-line growth in Q1. Total sales grew by 22.6% this quarter, driven by all three therapeutic areas. We're pleased to see the very strong performance of our portfolio outside somatolin, which grew by 27.5% in the three-month period. Based on this continued solid momentum and strong growth, We confirm our 2026 guidance with total sales growth greater than 13% at constant exchange rates and a core operating margin greater than 35% of sales. Turning to the pipeline, we were delighted to announce the approval of Agenda following the positive CHMP opinion in the European Union as the first targeted therapy in relapsed or refractory pediatric low-grade glioma, regardless of BRAF alteration. Looking ahead, 2026 promises to be an exciting year for our pipeline, with several key milestones, including three pivotal phase three readouts expected in H2 2026, as well as the launch of three late-stage programs starting this year. Please turn to slide five. Our Q1 ...